Crossmark

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

Crossref DOI link: https://doi.org/10.1007/s00125-020-05227-z

Published Online: 2020-08-05

Published Print: 2020-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hannelius, Ulf https://orcid.org/0000-0003-1562-437X
Beam, Craig A. https://orcid.org/0000-0002-8772-7661
Ludvigsson, Johnny https://orcid.org/0000-0003-1695-5234
Funding

Funding for this research was provided by:

Linköping University
License Information

Text and Data Mining valid from 2020-08-05

Version of Record valid from 2020-08-05
More Information

Article History

Received: 28 April 2020

Accepted: 11 June 2020

First Online: 5 August 2020